TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04348617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Description: 50 minutes of moderate exercise on treadmill

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Description: 50 minutes of moderate exercise on treadmill

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest
Description: 50 minutes of rest or sedentary activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest
Description: 50 minutes of rest or sedentary activity
Study: NCT05199142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDI-118
Description: SDI-118 Powder in Capsules (PiC) are presented as Drug Substance in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules. No excipients are added.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Matching Placebo for SDI-118 PiC is equivalent dose of mannitol (an inert excipient) in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules.
Study: NCT04960306

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal filtrate transplantation
Description: Patients will receive 5-8 encapsulated lyophilized fecal filtrate transplantations in enterosolvent, size 0 capsules. Before intervention patients will receive proton pump inhibitors and prokinetics. After the preparation, the participants will be instructed to swallow the capsules one by one within 5 minutes with fluid to help to swallow the capsules.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fecal microbiota transplantation
Description: Patients will receive 5-8 encapsulated lyophilized conventional fecal microbiota transplantations in enterosolvent, size 0 capsules. Before intervention patients will receive proton pump inhibitors and prokinetics. After the preparation, the participants will be instructed to swallow the capsules one by one within 5 minutes with fluid to help to swallow the capsules.
Study: NCT04887246

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccines
Description: COVID-19 vaccines available at Colombia
Study: NCT06337825

Intervention type: BEHAVIORAL
Intervention: Activity Tracker (Fitbit)
Description: Wearable, activity tracker

Intervention type: BEHAVIORAL
Intervention: Activity Tracker (Fitbit)
Description: Wearable, activity tracker

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1C
Description: Average blood glucose (sugar) levels reported as a percentage

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1C
Description: Average blood glucose (sugar) levels reported as a percentage

Intervention type: BEHAVIORAL
Intervention: The PROMPT Questionnaire
Description: The PROMPT Questionnaire which is a 30-question previously validated assessment for non-specific symptoms in PHPT, will be administered to patients preoperatively and at 2-weeks and 6-months postoperatively

Intervention type: BEHAVIORAL
Intervention: The PROMPT Questionnaire
Description: The PROMPT Questionnaire which is a 30-question previously validated assessment for non-specific symptoms in PHPT, will be administered to patients preoperatively and at 2-weeks and 6-months postoperatively
Study: NCT04333472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piclidenoson
Description: Piclidenoson 2 mg orally every 12 hours for up to 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally every 12 hours for up to 28 days
Study: NCT04950959

Intervention type: DEVICE
Intervention: Hands-free, user-controlled robotic system intended to assist in the planning and advancement of an instrument during CT guided percutaneous procedures. T
Description: The system is used for trajectory planning and is intended to assist the physician in the positioning of an instrument, such as a needle, where CT imaging is used for target trajectory planning and intraoperative tracking. The XACT ACE Robotic System uses a computerized quantitative guidance system, which provides real-time, accurate needle guidance, including advancement and steering of the needle from the entry point on the subject's body to the target point within the body.
Study: NCT03613064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Socially Enhanced Transitional Care Intervention
Description: Components: 1) Standardized social vulnerabilities assessment tool, to be developed and incorporated into admission workflows. 2) Electronic community service referrals to existing community resources (i.e. food banks, shelters, community rehab), via the Dallas IEP or other information technology platform, for material (food, housing) and psychosocial needs (mental health/drug treatment). 3) Community-based cardiovascular self-management interventions, to be developed and piloted in conjunction with #3 - e.g., customized 'heart healthy' food baskets for CHF/IHD; risk factor monitoring (i.e., weight and blood pressure measurement at food banks, shelters, churches, modeled on the barber shop hypertension intervention); and 'heart buddy' support groups for CHF and IHD at community sites.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Socially Enhanced Transitional Care Intervention
Description: Components: 1) Standardized social vulnerabilities assessment tool, to be developed and incorporated into admission workflows. 2) Electronic community service referrals to existing community resources (i.e. food banks, shelters, community rehab), via the Dallas IEP or other information technology platform, for material (food, housing) and psychosocial needs (mental health/drug treatment). 3) Community-based cardiovascular self-management interventions, to be developed and piloted in conjunction with #3 - e.g., customized 'heart healthy' food baskets for CHF/IHD; risk factor monitoring (i.e., weight and blood pressure measurement at food banks, shelters, churches, modeled on the barber shop hypertension intervention); and 'heart buddy' support groups for CHF and IHD at community sites.
Study: NCT05142306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-HIG
Description: Anti-SARS-CoV-2 Immunoglobulin (Human) \[COVID-HIG\] is a purified liquid immunoglobulin G (IgG) preparation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-HIG
Description: Anti-SARS-CoV-2 Immunoglobulin (Human) \[COVID-HIG\] is a purified liquid immunoglobulin G (IgG) preparation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-HIG
Description: Anti-SARS-CoV-2 Immunoglobulin (Human) \[COVID-HIG\] is a purified liquid immunoglobulin G (IgG) preparation
Study: NCT04280003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alogenic adipose tissue-derived stem cells
Description: Concentration of the cells: 10 million cells / ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: Placebo intravenous solution, same appearance stem cells solution
Study: NCT06148831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infant Carrier
Description: The assigned home visitor will provide a participant with an infant carrier and will watch a short training video on how to use the carrier, including a demonstration of safe and ergonomic use. The home visitor will support the client to practice using the carrier and will provide materials to support continued learning.~All home visitors participated in an infant carrier training developed by Nurturely, centered on carrying as a cultural practice, utilizing culturally relevant visuals as well as easy-to-remember acronyms to promote safe and ergonomic use (i.e., the STOP acronym developed by Nurturely, signifying that all knots are Secure, infant is attached high enough to kiss the top of their head and Tight to the caregiver's body, nose and mouth are visible and airway is Open, and hips are Positioned in an ergonomic spread squat).
Study: NCT05817461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0780 tablet
Description: oral, fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD0780 Solution for Infusion
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD0780 Oral Solution
Description: oral, fasted
Study: NCT04263519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Oral Immunosuppressant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Oral Immunosuppressant
Study: NCT05204394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500A-LAI
Description: Injectable nanoformulation of depulfavirine (parent drug of elsulfavirine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500A-LAI
Description: Injectable nanoformulation of depulfavirine (parent drug of elsulfavirine)

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Any oral 1st line approved HIV treatment regimen
Study: NCT05454410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821 Subcutaneous Injection - low dose
Description: MIJ821 supplied in vials as a powder for solution for injection, to be reconstituted, and administered as a single subcutaneous injection on Day 1
Study: NCT05724082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clean Air Intervention
Description: Based on findings from preliminary focus groups/in-depth interviews, staff will introduce various components of established clean air interventions to each household. Each household will receive interventions, depending on their known risk factors, exposures, and willingness to trial the intervention.~Study staff will ask the primary cook to complete a time-activity diary during the intervention period that includes cooking episodes, duration of cooking, stove(s) used, type of food cooked, and number of people for whom the meal was cooked. Staff will continuously monitor use of the LPG/pellet stove and any other stoves owned by the household with the Berkeley Stove Use Monitoring System, a temperature logger attached to the stove to quantify the number of stove uses / time of use . Study staff will use similar loggers to monitor use of other devices installed including the air purifiers, lighting etc.
Study: NCT06154018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protamin
Description: ACT and Clot- Pro test will be ran after initial and possible next protamine administrations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protamin
Description: ACT and Clot- Pro test will be ran after initial and possible next protamine administrations
Study: NCT05454410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821 Subcutaneous Injection - medium dose
Description: MIJ821 supplied in vials as a powder for solution for injection, to be reconstituted, and administered as a single subcutaneous injection on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821 Subcutaneous Injection - high dose
Description: MIJ821 supplied in vials as a powder for solution for injection, to be reconstituted, and administered as a single subcutaneous injection on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Subcutaneous Injection
Description: 0.9% sodium chloride solution to be administered as a single subcutaneous injection on Day 1
Study: NCT05745792

Intervention type: OTHER
Intervention: Description of clinical, immunological and tumor features of patients harboring Hu Abs
Description: This observationnal study involves clinical data and bio. samples (DNA and tumors block). Demographic and clinical data already in French Reference Center on PNS database will be reviewed. Additional data will be obtained from the referral physicians. The results of diagnostic tests performed to detect Hu-Abs in the patients are already in this database and will be retrospectively analyzed. In addition, the 4 available techniques (immunofluorescence, commercial immunodot, Western blot, and CBA) will be performed from Jan. 2022 to Dec. 2022.Tumor samples from 2 cohorts will be analyzed: (i) tumors of patients with Hu-Abs and PNS, and (ii) tumors of patients without PNS (mostly SCLC). After selecting patients, the study will involve 3 steps: (i) pathological confirmation; (ii) DNA sequencing and CNV analysis (panel of genes involved in anti-Hu autoimmunity; mainly ELAVL1 to 4, encoding for HuA to HuD, the 4 main proteins of the Hu family); and (iii) whole-genome RNA sequencing.
Study: NCT06224712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arogya Sangama
Description: Using human-centered design, the investigators will work wit the community to develop a prototype Arogya Sangama model to identify methods to bring GPTF and HWC service providers to create ideas, systems, processes, services, and delivery strategies for the GPTFs. They will help identify and prioritize interventions and address barriers to usability. There will also be capacity building of GPTFs to implement the interventions identified.
Study: NCT06055036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Black Impact Intervention
Description: The Black Impact intervention is an academic-community-government partnership adapted from the Diabetes Prevention Program and American Heart Association Check, Change, Control programs based on stakeholder feedback and to afford incorporation of additional evidence-based strategies for influencing target outcomes. The intervention is a 24-week community-based lifestyle intervention to improve cardiovascular health among Black men. Each participant will be assigned to a group with \>5 participants based on participant proximity to a central community meeting location. Each team will be guided weekly by a health coach who delivers content and coaching around the lifestyle intervention modeled on the diabetes prevention program and check, change, control blood pressure program, a community health worker who helps to address social needs and connects participants to primary care services, and a trainer who leads physical activity. Teams meet for 90 minutes per week.
Study: NCT05087862

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided pericapsular nerves group of the hip block
Description: After the ultrasound-guided insertion of a block needle at the level of the inguinal ligament, the needle will be advance into the plane between the iliac bone periosteum and the tendon of the iliopsoas muscle in order to inject 20 mL of adrenalized 0.5% bupivacaine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular local anesthetic infiltration of the hip
Description: Intraoperatively, 60 mL of adrenalized 0.25% bupivacaine plus ketorolac 30 mg will be infiltrated by the surgeon.
Study: NCT06139393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR091506 tablets + placebo of febuxostat tablets
Description: HR091506 tablets 20mg qd + placebo of febuxostat tablets 20mg qd from Week 1 to 4, HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd from Week 5 to 28.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: febuxostat tablets + placebo of HR091506 tablets
Description: febuxostat tablets 20mg qd + placebo of HR091506 tablets 20mg qd from Week 1 to 4, febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd from Week 5 to 28.
Study: NCT05124561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
Description: Nebulized inhalation through the mouth

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nebulized inhalation through the mouth
Study: NCT06167590

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: GAPsy protocol
Description: Each participant will undergo a 7 T multimodal neuroimaging session, including T1-weighted, 1H-MRS and fMRI. Each participant will also be assessed through a structured clinical interview (SCID-I e SCID-II) and will be administered scales such as HAM-A, HAM-D, BPRS and MADRS.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: GAPsy protocol
Description: Each participant will undergo a 7 T multimodal neuroimaging session, including T1-weighted, 1H-MRS and fMRI. Each participant will also be assessed through a structured clinical interview (SCID-I e SCID-II) and will be administered scales such as HAM-A, HAM-D, BPRS and MADRS.
Study: NCT05697926

Intervention type: OTHER
Intervention: No intervention
Description: This is a preclinical study. No intervention will be performed.
Study: NCT05611450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: disease self-management application
Description: The mHealth application provide disease self-management knowledge and skills and also has the functions of level of skin toxicity warning, uploading photos of skin toxicity, and interacting with healthcare professionals.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: disease self-management application
Description: The mHealth application provide disease self-management knowledge and skills and also has the functions of level of skin toxicity warning, uploading photos of skin toxicity, and interacting with healthcare professionals.
Study: NCT04991220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoxygenation
Description: Taking 8 deep breaths at 10 l/min of 100% oxygen for 1 minute with forced inspiration for pre-oxygenation
Study: NCT06373666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spatz4 Adjustable Balloon System
Description: Implantation of Spatz4 Adjustable Balloon system for weight loss treatment for Overweight and Obese patients and Adjustment of the balloon volume at week 16
Study: NCT06528626

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: rapid HIV and HCV serological tests
Description: In the standard of care branch (SOC), the health personnel will ask people a series of questions to identify the HIV risk exposition, and also they will be provided pop-up computer alerts of HIV indicator conditions in the electronic medical record, moreover HIV and HCV serological tests will be carried out in the reference laboratory, while in the intervention branch in addition to the SOC, a SQ-R\&IC of HIV and HCV will be made available to the HC population, through a quick response (QR) code, as well as HIV and HCV RT.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: rapid HIV and HCV serological tests
Description: In the standard of care branch (SOC), the health personnel will ask people a series of questions to identify the HIV risk exposition, and also they will be provided pop-up computer alerts of HIV indicator conditions in the electronic medical record, moreover HIV and HCV serological tests will be carried out in the reference laboratory, while in the intervention branch in addition to the SOC, a SQ-R\&IC of HIV and HCV will be made available to the HC population, through a quick response (QR) code, as well as HIV and HCV RT.
Study: NCT05311514

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic platelet lysate eye drops
Description: Eye drops

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic platelet lysate eye drops
Description: Eye drops
Study: NCT05800899

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Interviewing
Description: Standard non-adapted brief motivational interviewing based on motivational interviewing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally adaptation brief motivational interviewing
Description: culturally adapted brief motivational interviewing based on motivational interviewing.
Study: NCT04908150

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core training
Description: A total of 12 sessions were carried out, which lasted for 4 weeks, with a frequency of 3 sessions/ week. The duration of each session was 11 minutes 30 seconds. The working time of each exercise was 30 seconds with a 5 seconds rest between exercises, meaning that each exercise cycle lasted for 2.50 seconds. Three exercise cycles were performed with a 90 seconds rest between each one of them

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core training
Description: A total of 12 sessions were carried out, which lasted for 4 weeks, with a frequency of 3 sessions/ week. The duration of each session was 11 minutes 30 seconds. The working time of each exercise was 30 seconds with a 5 seconds rest between exercises, meaning that each exercise cycle lasted for 2.50 seconds. Three exercise cycles were performed with a 90 seconds rest between each one of them
Study: NCT04794348

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma (FFP)
Description: Autologous units of fresh frozen plasma collected from the subject by plasmapheresis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Freeze Dried Plasma (FDP)
Description: Autologous units of freeze dried plasma manufactured from plasma collected from the subject by plasmapheresis
Study: NCT06068374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Break of sedentary behavior with dual task
Description: Patients will interrupt sedentary behavior performing walking and cognitive activities simultaneously

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Break of sedentary behavior with walking
Description: Patients will interrupt sedentary behavior performing walking
Study: NCT04896801

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided RT
Description: The dose to the planning target volume (PTV) is 36 Gy (5 x 7.2 Gy) prescribed on the 90% isodose line. The clinical target volume (CTV) is receiving 40 Gy (5 x 8 Gy = 100%). A simultaneous integrated boost (SIB) up to a total dose of 42 Gy (5 x 8.4 Gy = 105%) is delivered to the gross tumor volume (GTV), if present. In addition, relative sparing of the urethra will be applied by avoiding hotspots (V40 Gy \< 1cc) in the urethra. Baseline and adapted treatment plans are generated using intensity-modulated RT
Study: NCT05705479

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bankart + Remplissage Procedure
Description: Participants will undergo arthroscopic stabilization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Latarjet Procedure
Description: Participants will undergo open or arthroscopic Latarjet procedure.
Study: NCT05161871

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cathodal transcranial direct current stimulation
Description: The cathodal transcranial direct current stimulation protocol will consist in five daily sessions, each lasting 20 min. The montage will provide a bilateral stimulation on occipital areas, with the reference anodal electrodes positioned on the M1 areas. The stimulation will be applied via 4 conductive-rubber square electrodes (5x5 cm) placed in sponges saturated with high conductivity gel and connected to a battery-operated stimulator system. Direct current with maximal intensity of 1.5 mA with be provided for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cathodal transcranial direct current stimulation
Description: Sham stimulation will be performed by the same protocol as active stimulation; however, the device will be switched off 30 seconds after the beginning of stimulation. This way, the patient will experience the same sensations as with active stimulation without receiving actual stimulation.